(0.10%) 5 253.92 points
(0.07%) 39 789 points
(-0.11%) 16 381 points
(2.21%) $83.15
(3.61%) $1.780
(1.35%) $2 242.60
(0.91%) $24.98
(1.34%) $921.90
(0.35%) $0.927
(0.76%) $10.85
(0.12%) $0.792
(0.14%) $92.57
Live Chart Being Loaded With Signals
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States...
Stats | |
---|---|
Today's Volume | 3 000.00 |
Average Volume | 501.00 |
Market Cap | 8.87M |
EPS | $0.0100 ( 2023-11-21 ) |
Next earnings date | ( $0 ) 2024-04-04 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 12.14 |
ATR14 | $0 (0.00%) |
Medicure Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Medicure Inc. Financials
Annual | 2022 |
Revenue: | $23.07M |
Gross Profit: | $16.08M (69.69 %) |
EPS: | $0.130 |
Q3 | 2023 |
Revenue: | $5.00M |
Gross Profit: | $3.64M (72.77 %) |
EPS: | $0.0100 |
Q2 | 2023 |
Revenue: | $5.99M |
Gross Profit: | $4.07M (67.93 %) |
EPS: | $0.0242 |
Q1 | 2023 |
Revenue: | $5.63M |
Gross Profit: | $3.80M (67.45 %) |
EPS: | $0.0300 |
Financial Reports:
No articles found.
Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators